May 28, 2015 / 9:48 PM / 2 years ago

Heron's nausea drug meets goal in late-stage trial, shares soar

(Reuters) - Heron Therapeutics Inc said its experimental drug for treating chemotherapy-induced nausea and vomiting (CINV) met its main goal in a late-stage trial.

The company, whose shares were up 41 percent in extended trading, said it expects to resubmit a marketing application for the drug to the U.S. FDA in mid-2015.

The company had filed for marketing application for Sustol twice but the FDA had sought additional data.

The drug, Sustol, in combination with two other drugs, was compared with a standard-of-care three-drug regimen.

The percentage of patients who achieved the main goal of complete response was significantly higher in the Sustol group.

Heron shares had closed at $12.35 on the Nasdaq on Thursday.

Reporting by Shailesh Kuber; Editing by Don Sebastian

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below